The quiet success of a vaccine can be a dangerous thing. For decades, Haemophilus influenzae type B, or Hib, existed as a specter in pediatricians’ memories – a disease capable of causing meningitis, pneumonia, and even death in up to 5% of those infected, roughly 1,000 children annually in the United States during peak incidence. Now, a handful of recent cases, including two fatalities, are prompting a difficult question: are we prepared for the return of a disease we believed we’d conquered? The concern isn’t simply about a rise in case numbers – currently at eight reported to the CDC as of March 28th, 2025, still far below the 20,000 seen annually before the vaccine – but about a potential erosion of clinical vigilance and the consequences of declining vaccination rates.
The story of Hib is a triumph of medical intervention. Introduced in the 1980s, the Hib vaccine rapidly drove down infection rates by over 99%. Infants receive a series of three or four doses starting at two months old, providing robust protection against this once-common bacterial infection. This success, however, has created a generation of medical professionals who may never have directly confronted the severity of invasive Hib disease. Eehab Kenawy, a pediatrician in Panama City, Florida, noted that he hadn’t encountered the infection in his 27 years of practice until recently, when his hospital’s intensive care unit admitted two severe cases within six months in 2025. One, a four-month-old, tragically died; the other, a two-year-old, suffered brain abscesses and seizures with lasting neurological effects. These cases, occurring in a tourist destination, raise the possibility of undetected spread, particularly as children travel and interact with varying levels of community immunity.
Original reporting: USA Today.
What’s crucial to understand is the distinction between alarmist headlines and the study’s actual findings. Reports of a “resurgence” of Hib are, at this point, based on a small cluster of cases, not a widespread outbreak. The CDC maintains that it is not currently observing an increase in preventable invasive Hib infections. However, the cases are concerning precisely because they are rare. The very infrequency of Hib in vaccinated populations means that doctors may be less likely to consider it in their differential diagnosis, potentially delaying treatment and increasing the risk of severe outcomes. Dr. Mathuram Santosham of Johns Hopkins University, a pioneer in the development of the Hib vaccine, expressed this fear, noting that the near-elimination of the disease is “frightening, not only for Hib, but for other diseases.”
The emerging pattern of these cases – unvaccinated children experiencing severe illness – is directly linked to declining vaccination rates. Dozens of states offer broad exemptions for religious or personal beliefs, and Florida is even considering eliminating school-entry vaccination requirements altogether. This trend mirrors the recent resurgence of measles, a stark reminder of the protective power of herd immunity and the risks of its erosion. Dr. Kathryn Edwards of Vanderbilt University Medical Center emphasized the need for parents to understand the risks of foregoing vaccination, and for physicians to remain vigilant in recognizing and responding to potential cases. The challenge isn’t simply convincing hesitant parents, but also re-educating a medical workforce that may have lost firsthand experience with the devastating consequences of Hib.
Limitations to consider are significant. The cases in Florida involved children visiting from out of state, making it difficult to assess the true prevalence of Hib in the local community. Furthermore, recent cuts to CDC surveillance and reporting systems may hinder early detection and tracking of cases. Dr. Paul Offit of the Children’s Hospital of Philadelphia highlighted this concern, questioning “What’s really going on?” and pointing to the potential for undetected spread. The lack of robust federal monitoring makes it harder to determine whether these cases represent isolated incidents or the beginning of a larger trend.
Looking ahead, the critical next step is strengthening surveillance systems and improving data collection to accurately monitor Hib incidence. Beyond that, research should focus on understanding the factors driving vaccine hesitancy and developing targeted interventions to address parental concerns. Perhaps most importantly, medical education must prioritize reinforcing the clinical recognition of Hib and other vaccine-preventable diseases. We need to ask ourselves: if Hib cases continue to emerge, even in small numbers, will our healthcare system be prepared to respond effectively, or will we risk repeating the tragic experiences of a generation ago? The answer hinges not just on the vaccine itself, but on our collective commitment to maintaining the vigilance that eradicated this once-feared disease.
